- Home
- JVSA vs ACHV Comparison
JVSA vs ACHV Comparison
Compare JVSA & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JVSA
- ACHV
- Stock Information
- Founded
- JVSA 2021
- ACHV N/A
- Country
- JVSA Hong Kong
- ACHV United States
- Employees
- JVSA N/A
- ACHV N/A
- Industry
- JVSA
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- JVSA
- ACHV Health Care
- Exchange
- JVSA NYSE
- ACHV Nasdaq
- Market Cap
- JVSA 83.2M
- ACHV 72.5M
- IPO Year
- JVSA 2024
- ACHV N/A
- Fundamental
- Price
- JVSA $3.52
- ACHV $2.11
- Analyst Decision
- JVSA
- ACHV Strong Buy
- Analyst Count
- JVSA 0
- ACHV 3
- Target Price
- JVSA N/A
- ACHV $14.33
- AVG Volume (30 Days)
- JVSA 88.5K
- ACHV 1.1M
- Earning Date
- JVSA 01-01-0001
- ACHV 08-12-2025
- Dividend Yield
- JVSA N/A
- ACHV N/A
- EPS Growth
- JVSA 719.53
- ACHV N/A
- EPS
- JVSA 0.27
- ACHV N/A
- Revenue
- JVSA N/A
- ACHV N/A
- Revenue This Year
- JVSA N/A
- ACHV N/A
- Revenue Next Year
- JVSA N/A
- ACHV N/A
- P/E Ratio
- JVSA $39.39
- ACHV N/A
- Revenue Growth
- JVSA N/A
- ACHV N/A
- 52 Week Low
- JVSA $3.12
- ACHV $1.84
- 52 Week High
- JVSA $19.28
- ACHV $5.31
- Technical
- Relative Strength Index (RSI)
- JVSA N/A
- ACHV 53.11
- Support Level
- JVSA N/A
- ACHV $3.44
- Resistance Level
- JVSA N/A
- ACHV $3.90
- Average True Range (ATR)
- JVSA 0.00
- ACHV 0.28
- MACD
- JVSA 0.00
- ACHV -0.01
- Stochastic Oscillator
- JVSA 0.00
- ACHV 56.99
About JVSA JVSPAC ACQUISITION CORP
JVSPAC Acquisition Corp is blank check company.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.